Developer docs
API playgroundTry for free, no card

Search company profiles

MSPharma

Full company profile

uuid0002xju

Namestring
MSPharma
Legal namestring
MS Pharma International AG
Websiteurl
mspharma.com
Company typeenum
Private
Founded yearint
2011
Descriptiontext

MS Pharma is a privately held, Jordan-headquartered multinational pharmaceutical group that develops, manufactures, and commercializes generic and specialty medicines across the Middle East and North Africa (MENA). The group operates five manufacturing facilities across Jordan (United Pharmaceuticals/UPM for non-sterile oral solids and cephalosporins; MS Pharma Injectables/MSPI for sterile injectables), Algeria (El Kendi, the country's largest pharmaceutical production facility with a new oncological unit added in 2025), and Saudi Arabia (an oral solids site plus the newly inaugurated MENA-first biologics manufacturing hub in Riyadh), producing a portfolio of 300 INNs spanning cardiovascular, central nervous system, respiratory, and oncology therapeutic areas in solids, liquids, cytotoxics, and sterile injectable dosage forms.

The company's revenue model rests on three pillars: direct sales of generics and specialty pharmaceuticals through its own sales and marketing offices in 10+ MENA countries (Algeria, Jordan, Saudi Arabia, UAE, Kuwait, Oman, Bahrain, Qatar, Iraq) with distribution to 70+ countries; exclusive licensing, supply, and commercialization agreements with global pharmaceutical innovators seeking MENA market access (notably Formycon AG for the FYB206 pembrolizumab biosimilar); and contract manufacturing of biologics and complex peptides at its EMA/FDA-aligned Riyadh facility — the first site in the Kingdom to receive SFDA BPF approval for biological product manufacturing and the first in MENA to operate in-house bioanalytical testing laboratories. Products are procured via tenders, institutional buyers, and government health systems rather than published list prices.

Customer segments span healthcare providers and patients across MENA (primary segment), global pharmaceutical companies seeking GMP-certified MENA/EU/US market entry through licensing or contract manufacturing, and biopharmaceutical innovators/biosimilar developers requiring regional commercialization partners. The Sukhtian family retains board control (four of seven directors), while executive leadership is run from a Corporate Management Office (MS Pharma International AG) in Zug, Switzerland, led by CEO Kalle Känd. In May 2026, Olayan Financing Company took a strategic minority equity stake to support further biosimilar and manufacturing expansion aligned with Saudi Vision 2030.

Short descriptiontext

MS Pharma is a privately held Jordan-headquartered multinational pharmaceutical company that develops, manufactures, and distributes generic, specialty, and biologic medicines across the MENA region through five production facilities in Jordan, Algeria, and Saudi Arabia, serving healthcare providers, government health systems, and global pharma partners in 70+ countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersAmman, Jordan
HQ citystring
Amman
HQ countrystring
Jordan
HQ regionstring
Middle East
Markets served

Serves global market

Keyword5 values
generic pharmaceuticals, biosimilar manufacturing, specialty medicines, sterile injectables, biologics manufacturing
Industry3 codes
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAMAD
Specialty Pharma & Biologics Distribution (GDP-compliant)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Supply Chain, Logistics & Cold Chain for Life Sciences
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Generic Pharmaceuticals Manufacturing
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Generic and Specialty Pharmaceutical Sales
TypeHardware Sales
Description

Primary revenue stream from sales of generic and specialty medicines across 70+ countries, with a diversified product portfolio spanning cardiovascular, central nervous system, respiratory, oncology, and other therapeutic areas in solid, liquid, cytotoxic, and sterile injectable dosage forms.

mspharma.com
2Licensing, Supply, and Commercialization Partnerships
TypeLicensing Royalties
Description

Revenue from exclusive licensing, supply, and commercialization agreements with global pharmaceutical companies seeking access to MENA markets (e.g., exclusive commercialization of Formycon's FYB206 / Keytruda biosimilar for the MENA region). Includes potential future expansion and technology transfer.

prnewswire.co.uk
3Biosimilars and Biologics Portfolio Revenue
TypeHardware Sales
Description

Revenue stream from biosimilars (e.g., FYB206 pembrolizumab biosimilar) and locally manufactured biologics (monoclonal antibodies, complex peptides) in Saudi Arabia, leveraging first-mover position as the first provider of locally manufactured biologics in the Saudi market.

prnewswire.co.uk
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1El Kendi
Description

Algerian generic pharmaceutical subsidiary brand; the leading generic pharmaceutical company in Algeria with more than 75 INNs on the market.

mspharma.com
+2 more records
Core offering1 text field

MS Pharma is a multinational pharmaceutical company that develops, manufactures, and distributes generic and specialty medicines, including biosimilars and biologics, across the MENA region and 70+ countries worldwide. Operating five production facilities in Jordan, Algeria, and Saudi Arabia, the company holds 2,000+ marketing authorizations across 300 INNs spanning cardiovascular, CNS, respiratory, and oncology therapeutic areas. It also serves as a strategic manufacturing and partnership platform for global pharmaceutical companies seeking MENA, EU, and US market access through licensing, supply, and commercialization agreements.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • First provider of locally manufactured biologics in Saudi Arabia through SFDA BPF-approved facility
+4 more records
Product overview1 text field

MS Pharma operates a platform-plus-subsidiaries product architecture centered on a single diversified pharmaceutical offering — generic and specialty medicines plus a growing biologics/biosimilars platform — delivered through multiple coordinated manufacturing and commercial brands. The Generic Pharmaceuticals Portfolio (active in cardiovascular, CNS, respiratory, and oncology) is produced across subsidiaries including United Pharmaceuticals (UPM) for non-sterile oral and cephalosporin manufacturing in Jordan, MS Pharma Injectables (MSPI) for sterile injectables in Jordan, and El Kendi in Algeria for solid dose, liquid, cream, and (since 2025) oncology products. Layered on top is the Biologics and Biosimilars Portfolio, anchored by MS Pharma's newly inaugurated Riyadh biologics hub (monoclonal antibodies, peptides, fill/finish) and including the in-licensed FYB206 pembrolizumab biosimilar partnered with Formycon for the MENA region. Together with Specialty Medicines, these form a unified pharma product portfolio marketed in 70+ countries under a single MS Pharma brand.

Product and service5 records
1Generic Pharmaceuticals Portfolio
CategoryGeneric Pharmaceuticals
Description

A wide range of generic medicines marketed across multiple therapeutic areas including cardiovascular, central nervous system, respiratory, and oncology, with dosage forms spanning solids, liquids, cytotoxic drugs, and sterile injectables. Backed by 2,000+ marketing authorisations and 300 INNs/molecules, produced across subsidiaries in Jordan, Algeria, and Saudi Arabia.

2Biologics and Biosimilars Portfolio
CategoryBiologics and Biosimilars
Description

Biotech and biosimilar product line manufactured at MS Pharma's new Riyadh biologics facility, with capabilities for monoclonal antibodies, complex peptides, liquid vials, freeze-dried vials, cartridges, and prefilled syringes/pens. Designed to EMA and FDA standards with SFDA GMP approval.

3FYB206 (pembrolizumab biosimilar)
CategoryIn-licensed Biosimilar
Description

Biosimilar candidate to Keytruda (pembrolizumab) for oncology, in-licensed from Formycon AG under an exclusive licensing and supply agreement for the MENA region, with potential for future expansion and technology transfer.

4Specialty Medicines
CategorySpecialty Pharmaceuticals
Description

Specialty pharmaceutical products including cytotoxic drugs and complex sterile injectables in therapeutic areas such as oncology, serving MENA, GCC, and African markets through the MSPI (MS Pharma Injectables) subsidiary in Jordan. The MSPI portfolio spans hematology, CNS, systemic anti-infectives, musculoskeletal, GI tract, and oncology with more than 100 products.

5Oncology Treatments (Algeria manufacturing unit)
CategoryOncology Treatments
Description

In 2025, a new dedicated manufacturing unit for oncological treatments was added to the El Kendi site in Algeria, expanding the local availability of cancer therapies and MS Pharma's specialized pharmaceutical production capabilities.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-12-04
Description

Formycon AG and MS Pharma entered into an exclusive licensing and supply agreement for the commercialization of FYB206, a biosimilar candidate to Keytruda® (pembrolizumab), in the Middle East and North Africa (MENA). The collaboration aims to increase access to this cancer drug across the region, with potential for future expansion and technology transfer. FYB206 is Formycon's pembrolizumab biosimilar candidate.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Jordan-headquartered multinational pharmaceutical company focused on generics, injectables, and branded products across MENA and the US. Most directly comparable to MS Pharma by geography, product mix (generics + injectables), and MENA leadership ambitions.

TypeDirect peer
Description

Saudi Arabia-based generics and specialty pharmaceutical manufacturer with a leading position in the Kingdom and MENA expansion. Comparable to MS Pharma Saudi's product portfolio and Kingdom-market focus.

3Julphar (Gulf Pharmaceutical Industries)
TypeDirect peer
Description

UAE-based regional pharmaceutical manufacturer producing generics, specialty, and biotech products across MENA. Comparable to MS Pharma in regional manufacturing footprint, product breadth, and GCC sales presence.

TypeDirect peer
Description

Saudi Arabia-headquartered pharmaceutical manufacturer producing generics and specialty products for the Kingdom and MENA. Direct comparable to MS Pharma Saudi in KSA generic and specialty manufacturing.

TypeBroad incumbent
Description

India-headquartered global pharmaceutical company with a strong MENA presence across generics, specialty, and increasingly biosimilars. Comparable in generic product breadth and emerging-market commercialisation model.

TypeBroad incumbent
Description

India-based global generic and specialty pharmaceutical manufacturer with growing MENA and biosimilar footprints. Comparable in generics-led revenue model and emerging-market distribution intensity.

7Sandoz (Novartis)
TypeBroad incumbent
Description

Global leader in generics and biosimilars, including MAb biosimilars. Comparable in biosimilar product category and the FYB206/pembrolizumab biosimilar competitive set MS Pharma is targeting in MENA.

TypeRegional player
Description

Egypt-headquartered generic pharmaceutical manufacturer with regional MENA reach. Comparable in Arab-market generics positioning, though with primary geographic focus on Egypt rather than Levant/GCC.

TypeEmerging player
Description

Switzerland-headquartered specialty and generics company with a meaningful MENA presence, where MS Pharma's CEO previously served. Comparable in specialty/out-licensing business model and MENA distribution intensity.

TypeEmerging player
Description

India-based pharmaceutical company focused on generics, specialty, and biosimilars with regulated-market and emerging-market distribution. Comparable in softgel/sterile capabilities and emerging-market partnership-led GTM.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks1 record

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries6 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MSPharma

Generic Pharmaceuticals Manufacturingmspharma.com

MS Pharma is a privately held Jordan-headquartered multinational pharmaceutical company that develops, manufactures, and distributes generic, specialty, and biologic medicines across the MENA region through five production facilities in Jordan, Algeria, and Saudi Arabia, serving healthcare providers, government health systems, and global pharma partners in 70+ countries.

What MSPharma does

MS Pharma is a privately held, Jordan-headquartered multinational pharmaceutical group that develops, manufactures, and commercializes generic and specialty medicines across the Middle East and North Africa (MENA). The group operates five manufacturing facilities across Jordan (United Pharmaceuticals/UPM for non-sterile oral solids and cephalosporins; MS Pharma Injectables/MSPI for sterile injectables), Algeria (El Kendi, the country's largest pharmaceutical production facility with a new oncological unit added in 2025), and Saudi Arabia (an oral solids site plus the newly inaugurated MENA-first biologics manufacturing hub in Riyadh), producing a portfolio of 300 INNs spanning cardiovascular, central nervous system, respiratory, and oncology therapeutic areas in solids, liquids, cytotoxics, and sterile injectable dosage forms.

The company's revenue model rests on three pillars: direct sales of generics and specialty pharmaceuticals through its own sales and marketing offices in 10+ MENA countries (Algeria, Jordan, Saudi Arabia, UAE, Kuwait, Oman, Bahrain, Qatar, Iraq) with distribution to 70+ countries; exclusive licensing, supply, and commercialization agreements with global pharmaceutical innovators seeking MENA market access (notably Formycon AG for the FYB206 pembrolizumab biosimilar); and contract manufacturing of biologics and complex peptides at its EMA/FDA-aligned Riyadh facility — the first site in the Kingdom to receive SFDA BPF approval for biological product manufacturing and the first in MENA to operate in-house bioanalytical testing laboratories. Products are procured via tenders, institutional buyers, and government health systems rather than published list prices.

Customer segments span healthcare providers and patients across MENA (primary segment), global pharmaceutical companies seeking GMP-certified MENA/EU/US market entry through licensing or contract manufacturing, and biopharmaceutical innovators/biosimilar developers requiring regional commercialization partners. The Sukhtian family retains board control (four of seven directors), while executive leadership is run from a Corporate Management Office (MS Pharma International AG) in Zug, Switzerland, led by CEO Kalle Känd. In May 2026, Olayan Financing Company took a strategic minority equity stake to support further biosimilar and manufacturing expansion aligned with Saudi Vision 2030.

MSPharma firmographics

Firmographics
Name
MSPharma
Legal name
MS Pharma International AG
Website
https://mspharma.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
MS Pharma is a privately held Jordan-headquartered multinational pharmaceutical company that develops, manufactures, and distributes generic, specialty, and biologic medicines across the MENA region through five production facilities in Jordan, Algeria, and Saudi Arabia, serving healthcare providers, government health systems, and global pharma partners in 70+ countries.
Ownership category
akta.pro rank

MSPharma industry classification

Industry
Product category
Generic Pharmaceuticals Manufacturing
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAMAD
Specialty Pharma & Biologics Distribution (GDP-compliant)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Supply Chain, Logistics & Cold Chain for Life Sciences

Keywords

  • Generic pharmaceuticals
  • Biosimilar manufacturing
  • Specialty medicines
  • Sterile injectables
  • Biologics manufacturing

Where MSPharma is headquartered

Location

Headquarters

HQ city
Amman
HQ country
Jordan
HQ region
Middle East

Markets served

MSPharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales

Revenue model

  1. Generic and Specialty Pharmaceutical Sales: Primary revenue stream from sales of generic and specialty medicines across 70+ countries, with a diversified product portfolio spanning cardiovascular, central nervous system, respiratory, oncology, and other therapeutic areas in solid, liquid, cytotoxic, and sterile injectable dosage forms.
  2. Licensing, Supply, and Commercialization Partnerships: Revenue from exclusive licensing, supply, and commercialization agreements with global pharmaceutical companies seeking access to MENA markets (e.g., exclusive commercialization of Formycon's FYB206 / Keytruda biosimilar for the MENA region). Includes potential future expansion and technology transfer.
  3. Biosimilars and Biologics Portfolio Revenue: Revenue stream from biosimilars (e.g., FYB206 pembrolizumab biosimilar) and locally manufactured biologics (monoclonal antibodies, complex peptides) in Saudi Arabia, leveraging first-mover position as the first provider of locally manufactured biologics in the Saudi market.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

MSPharma product offering

Product offering

Core offering

MS Pharma is a multinational pharmaceutical company that develops, manufactures, and distributes generic and specialty medicines, including biosimilars and biologics, across the MENA region and 70+ countries worldwide. Operating five production facilities in Jordan, Algeria, and Saudi Arabia, the company holds 2,000+ marketing authorizations across 300 INNs spanning cardiovascular, CNS, respiratory, and oncology therapeutic areas. It also serves as a strategic manufacturing and partnership platform for global pharmaceutical companies seeking MENA, EU, and US market access through licensing, supply, and commercialization agreements.

Product overview

MS Pharma operates a platform-plus-subsidiaries product architecture centered on a single diversified pharmaceutical offering — generic and specialty medicines plus a growing biologics/biosimilars platform — delivered through multiple coordinated manufacturing and commercial brands. The Generic Pharmaceuticals Portfolio (active in cardiovascular, CNS, respiratory, and oncology) is produced across subsidiaries including United Pharmaceuticals (UPM) for non-sterile oral and cephalosporin manufacturing in Jordan, MS Pharma Injectables (MSPI) for sterile injectables in Jordan, and El Kendi in Algeria for solid dose, liquid, cream, and (since 2025) oncology products. Layered on top is the Biologics and Biosimilars Portfolio, anchored by MS Pharma's newly inaugurated Riyadh biologics hub (monoclonal antibodies, peptides, fill/finish) and including the in-licensed FYB206 pembrolizumab biosimilar partnered with Formycon for the MENA region. Together with Specialty Medicines, these form a unified pharma product portfolio marketed in 70+ countries under a single MS Pharma brand.

Differentiator

Problem solved

Functional benefit

Brands

  • El Kendi: Algerian generic pharmaceutical subsidiary brand; the leading generic pharmaceutical company in Algeria with more than 75 INNs on the market.
  • UPM (United Pharmaceuticals)
  • MSPI (MS Pharma Injectables)

Products and services

  • Generic Pharmaceuticals Portfolio A wide range of generic medicines marketed across multiple therapeutic areas including cardiovascular, central nervous system, respiratory, and oncology, with dosage forms spanning solids, liquids, cytotoxic drugs, and sterile injectables. Backed by 2,000+ marketing authorisations and 300 INNs/molecules, produced across subsidiaries in Jordan, Algeria, and Saudi Arabia.
  • Biologics and Biosimilars Portfolio Biotech and biosimilar product line manufactured at MS Pharma's new Riyadh biologics facility, with capabilities for monoclonal antibodies, complex peptides, liquid vials, freeze-dried vials, cartridges, and prefilled syringes/pens. Designed to EMA and FDA standards with SFDA GMP approval.
  • FYB206 (pembrolizumab biosimilar) Biosimilar candidate to Keytruda (pembrolizumab) for oncology, in-licensed from Formycon AG under an exclusive licensing and supply agreement for the MENA region, with potential for future expansion and technology transfer.
  • Specialty Medicines Specialty pharmaceutical products including cytotoxic drugs and complex sterile injectables in therapeutic areas such as oncology, serving MENA, GCC, and African markets through the MSPI (MS Pharma Injectables) subsidiary in Jordan. The MSPI portfolio spans hematology, CNS, systemic anti-infectives, musculoskeletal, GI tract, and oncology with more than 100 products.
  • Oncology Treatments (Algeria manufacturing unit) In 2025, a new dedicated manufacturing unit for oncological treatments was added to the El Kendi site in Algeria, expanding the local availability of cancer therapies and MS Pharma's specialized pharmaceutical production capabilities.

Quantifiable outcome

  • First provider of locally manufactured biologics in Saudi Arabia through SFDA BPF-approved facility
  • +4 more outcomes

Companies that use MSPharma

Customer profile

Segments3 records

Ideal customer profiles3 records

MSPharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

MSPharma partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Formycon AGcoreOEM/ Whitelabel/ Licensing Partner · 4 December 2025Formycon AG and MS Pharma entered into an exclusive licensing and supply agreement for the commercialization of FYB206, a biosimilar candidate to Keytruda® (pembrolizumab), in the Middle East and North Africa (MENA). The collaboration aims to increase access to this cancer drug across the region, with potential for future expansion and technology transfer. FYB206 is Formycon's pembrolizumab biosimilar candidate.

Scale indicators13 records

Recent moves8 records

Expansion highlights7 records

MSPharma competitors and assessment

Company assessment

Direct peers

  • Hikma Pharmaceuticals: Jordan-headquartered multinational pharmaceutical company focused on generics, injectables, and branded products across MENA and the US. Most directly comparable to MS Pharma by geography, product mix (generics + injectables), and MENA leadership ambitions.
  • Tabuk Pharmaceuticals: Saudi Arabia-based generics and specialty pharmaceutical manufacturer with a leading position in the Kingdom and MENA expansion. Comparable to MS Pharma Saudi's product portfolio and Kingdom-market focus.
  • Julphar (Gulf Pharmaceutical Industries): UAE-based regional pharmaceutical manufacturer producing generics, specialty, and biotech products across MENA. Comparable to MS Pharma in regional manufacturing footprint, product breadth, and GCC sales presence.
  • SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances Corporation): Saudi Arabia-headquartered pharmaceutical manufacturer producing generics and specialty products for the Kingdom and MENA. Direct comparable to MS Pharma Saudi in KSA generic and specialty manufacturing.

Broad incumbents

  • Cipla: India-headquartered global pharmaceutical company with a strong MENA presence across generics, specialty, and increasingly biosimilars. Comparable in generic product breadth and emerging-market commercialisation model.
  • Aurobindo Pharma: India-based global generic and specialty pharmaceutical manufacturer with growing MENA and biosimilar footprints. Comparable in generics-led revenue model and emerging-market distribution intensity.
  • Sandoz (Novartis): Global leader in generics and biosimilars, including MAb biosimilars. Comparable in biosimilar product category and the FYB206/pembrolizumab biosimilar competitive set MS Pharma is targeting in MENA.

Regional players

Emerging players

  • Acino International: Switzerland-headquartered specialty and generics company with a meaningful MENA presence, where MS Pharma's CEO previously served. Comparable in specialty/out-licensing business model and MENA distribution intensity.
  • Strides Pharma Science: India-based pharmaceutical company focused on generics, specialty, and biosimilars with regulated-market and emerging-market distribution. Comparable in softgel/sterile capabilities and emerging-market partnership-led GTM.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks1 record

Key highlights7 records

Customer concentration

MSPharma social profiles

Digital presence

MSPharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MSPharma leadership team

Management profile

Number of profiles

Profiles10 records

MSPharma subsidiaries and ownership

Company hierarchy

Subsidiaries6 records

MSPharma funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MSPharma M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MSPharma

What does MSPharma do?

MS Pharma is a multinational pharmaceutical company that develops, manufactures, and distributes generic and specialty medicines, including biosimilars and biologics, across the MENA region and 70+ countries worldwide. Operating five production facilities in Jordan, Algeria, and Saudi Arabia, the company holds 2,000+ marketing authorizations across 300 INNs spanning cardiovascular, CNS, respiratory, and oncology therapeutic areas. It also serves as a strategic manufacturing and partnership platform for global pharmaceutical companies seeking MENA, EU, and US market access through licensing, supply, and commercialization agreements.

Is MSPharma a public or private company?

MSPharma is a private company. It is classified as family owned and is currently operating.

When was MSPharma founded?

MSPharma was founded in 2011. It employs 1,001 to 5,000 people.

Where is MSPharma based?

MSPharma is headquartered in Amman, Jordan, in the Middle East region.

How does MSPharma make money?

Three revenue lines are on record. Generic and Specialty Pharmaceutical Sales are the primary driver. The others are licensing, Supply, and Commercialization Partnerships and biosimilars and Biologics Portfolio Revenue.

Who are MSPharma's main competitors?

Direct peers on record are Hikma Pharmaceuticals, Tabuk Pharmaceuticals, Julphar (Gulf Pharmaceutical Industries) and SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances Corporation). Broad incumbents are Cipla, Aurobindo Pharma and Sandoz (Novartis). EIPICO (Egyptian International Pharmaceutical Industries Co.) is listed as a regional player. Emerging players are Acino International and Strides Pharma Science.

Does MSPharma have an API?

No public API is recorded for MSPharma.

What industry is MSPharma in?

MSPharma's product category is Generic Pharmaceuticals Manufacturing. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAGAHAL, GMP Scale-Up, Tech Transfer & Process Validation (PPQ). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GulfNewsUAE to expand local production of medicines for cancer and chronic diseasesADCAN Pharma and MS Pharma signed an agreement to manufacture and test medicines locally in the UAE, announced at the Abu Dhabi Future Health Summit. The partnership covers injectables, tablets, and biosimilars for cancer, chronic diseases, and other conditions, aiming to improve access and reduce dependence on international supply chains.EIN PresswireADCAN Pharma and MS Pharma Partner to Advance Pharmaceutical Localization in the UAE - Middle East Business News and Information - mid-east.infoADCAN Pharma and MS Pharma announced a strategic collaboration to localize biosimilars and injectables in the UAE, announced at the Abu Dhabi Future Health Summit. The partnership covers therapeutic areas including oncology, immunology, and cardiovascular care, with ADCAN establishing a UAE laboratory for monoclonal antibody testing.EIN PresswireADCAN Pharma and MS Pharma Partner to Advance Pharmaceutical Localization in the UAE - Middle East News 247ADCAN Pharma and MS Pharma announced a strategic collaboration to localize biosimilars and pharmaceutical products in the UAE, announced at the Abu Dhabi Future Health Summit. The partnership covers biosimilars, injectables, and oral solids across oncology, immunology, and other therapeutic areas, with ADCAN establishing a UAE laboratory for monoclonal antibody testing.The Pharma LetterMS Pharma wins investment from Olayan FinancingOlayan Financing Company made a minority equity investment in Jordan-based MS Pharma, a generic and biologic therapy developer. The partnership aims to support MS Pharma's growth, innovation, and regional expansion, and marks the start of a long-term collaboration with MS Pharma's existing majority shareholders.BioWorldFinancings for May 19, 2026Biopharma and med-tech companies raised money in public or private financings on May 19, 2026. The companies listed include MS Pharma, Orphai, Quince, Rein, and Silexion.PR NewswireMS Pharma Announces Strategic Growth Investment from Olayan Financing CompanyOlayan Financing Company made a minority equity investment in MS Pharma, issuing new share capital for cash. The partnership aims to expand MS Pharma's biosimilars portfolio and manufacturing capabilities across the MENA region, with plans to become the first supplier of locally manufactured biologics to Saudi Arabia.BioSpaceMS Pharma Announces Strategic Growth Investment from Olayan Financing CompanyOlayan Financing Company made a minority equity investment in MS Pharma, issuing new share capital for cash. The partnership aims to expand MS Pharma's biosimilars portfolio and manufacturing across the MENA region, with plans to become the first supplier of locally manufactured biologics to Saudi Arabia this year.YahooMS Pharma Establishes MENA's First Biologics Manufacturing Hub in Saudi Arabia, Advancing Regional Leadership and Global PartnershipsMS Pharma inaugurated its first biologics manufacturing facility in Saudi Arabia, receiving SFDA GMP approval. The USD 50 million plant produces monoclonal antibodies and complex peptides, with in-house bioanalytical labs. It aims to support global partners seeking access to MENA, EU, and US markets.AETOSWirePolpharma Biologics and MS Pharma Sign Licensing Agreements for Proposed Vedolizumab (PB016), Ocrelizumab (PB018) and Guselkumab (PB019) BiosimilarsPolpharma Biologics signed licensing agreements with MS Pharma to commercialize biosimilars for vedolizumab, ocrelizumab, and guselkumab in the MENA region. MS Pharma will handle registration, marketing, and distribution, while Polpharma retains development and manufacturing, with fill and finish moved to a Saudi Arabia facility.news.cision.comEnzymatica enters agreement with MS Pharma for MENAEnzymatica and MS Pharma agreed to market, distribute, and sell ColdZyme in MENA, covering 10 countries with a combined population of about 160 million. MS Pharma expects to launch the product under its registered trademarks in the first half of 2021. The company cites growing demand for non-prescription products amid the COVID-19 pandemic.